Chinese biotech company Abogen licensed its mRNA-TCE candidate ABO2203 to Novartis for $575M upfront and up to $7.8B in milestones. Meanwhile, Chinese research dominated ESMO 2026 with 30 late-breaking abstracts (1/3 of total) and 5 of 12 proffered paper presentations.
China's innovative pharma sector is significantly undervalued and poised for a 2027 breakout, driven by global deals and clinical data dominance.
Free preview — more China A-share & HK research · About Us · Legal & Privacy